I am a nuclear medicine physician and Deputy Chief of the Molecular Imaging and Therapy Service in the Department of Radiology. I have special expertise in oncologic imaging (in particular using PET/CT), as well as cardiac imaging and nuclear medicine therapies. I am an active member of several national and international imaging societies, including the Society of Nuclear Medicine and Molecular Imaging and the Radiological Society of North America, for which I organize and participate in regular educational lecture series. As a member of the imaging and lymphoma committees of the Alliance for Clinical Trials in Oncology, I organize and participate as an expert reader in national multicenter trials. I serve as a reviewer for a variety of imaging and oncology journals. Besides my clinical work, I am interested in how the medical industry is changing and the future of healthcare.
I am actively involved in clinical research. My current research interests include: assessing the role of PET/CT imaging in the management of cancer patients, in particular patients with lymphoma or cancers of the head and neck; the introduction and clinical evaluation of new PET radiotracers in oncology; the role of PET/CT imaging in radiotherapy planning and response assessment; and the development and evaluation of new techniques for motion control and quantification, which may aid in the detection, treatment planning, and response assessment of various cancers.
I am a member of the disease management teams for lymphoma and head and neck cancer at MSKCC.
- Clinical Expertise: Positron Emission Tomography/Computed Tomography (PET/CT) Body Imaging in Oncology; Cardiac Imaging; General Diagnostic and Therapeutic Nuclear Medicine
- Languages Spoken: English
- Education: MD, Humboldt University (Berlin)
- Residencies: University of California, Los Angeles, Medical Center
- Fellowships: University of California, Los Angeles, Medical Center
- Board Certifications: Nuclear Medicine (US); Nuclear Cardiology (US); Diagnostic Radiology and Nuclear Medicine (Germany)
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by Heiko Schöder
- A Phase I Study of Nivolumab Immunotherapy plus Standard Chemotherapy for Newly Diagnosed High-Risk Hodgkin Lymphoma
- A Phase Ib/II Study of Mocetinostat plus Brentuximab Vedotin in Patients with Recurrent or Persistent Hodgkin Lymphoma
- A Pilot Study Assessing a Special PET Scan to Help Guide the Biopsy of Histiocytic Disorders
- A Study Assessing the Predictive Value of Tumor Hypoxia (Low Oxygen Supply) in Patients with Non-Small Cell Lung Cancer
- Adoptive Transfer of Autologous T Cells Targeted to Prostate-Specific Membrane Antigen for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more